Blog
RSS FeedPosted by Michael Wonder on 23 Jun 2016
Agreement with Biotronik Australia for the supply of interventional cardiology devices
23 June 2016 - PHARMAC is pleased to announce the approval of an agreement with Biotronik Australia Pty Limited for the ...
Posted by Michael Wonder on 21 Jun 2016
Agreement with Smith & Nephew for the supply of orthopaedic trauma implants
21 June 2016 - PHARMAC is pleased to announce the approval of an agreement with Smith and Nephew for the supply ...
Posted by Michael Wonder on 12 Jun 2016
PHARMAC to fund melanoma drug
10 June 2016 - PHARMAC has negotiated a more than $100 million per year saving on the price of six medicines ...
Posted by Michael Wonder on 10 Jun 2016
PHARMAC to seek further advice on azithromycin funding proposal
10 June 2016 - PHARMAC received a number of high-quality, well considered responses to the proposal to amend the funding restrictions ...
Posted by Michael Wonder on 09 Jun 2016
Cancer drug 'a long time coming'
10 June 2016 - PHARMAC has been accused of leaving melanoma patients in suspense by not telling them earlier when their ...
Posted by Michael Wonder on 09 Jun 2016
Government announces new drug funding, including for advanced melanoma
9 June 2016 - Medicine to treat six diseases, including for advanced melanoma, will be available to New Zealanders. ...
Posted by Michael Wonder on 09 Jun 2016
Health sector feedback helps make the most of Government funding boost
9 June 2016 - PHARMAC is today announcing funding of six new treatments across important areas of health, including major advancements ...
Posted by Michael Wonder on 08 Jun 2016
New fund set up to support research into medicines usage in NZ
8 June 2016 - Why do people not take all the medicine prescribed for them? Why are there differences in the ...
Posted by Michael Wonder on 02 Jun 2016
Proposal for the supply of influenza vaccine
2 June 2016 - Following a request for proposals for the supply of influenza vaccine, issued on 3 February 2016, PHARMAC ...
Posted by Michael Wonder on 31 May 2016
New Zealand Pharmaceutical Schedule - 1 June 2016 update
1 June 2016 - The June 2016 update to the New Zealand Pharmaceutical Schedule sees the listing of one new medicine. ...
Posted by Michael Wonder on 30 May 2016
Proposals to widen funding access to important vaccines
30 May 2016 - PHARMAC is asking the public for feedback on proposals to widen funding access to the varicella (chickenpox) ...
Posted by Michael Wonder on 26 May 2016
New Zealand budget 2016: extra $2.2 billion pumped into health
26 May 2016 - An extra $2.2 billion will be pumped into health over four years to help cope with an ...
Posted by Michael Wonder on 23 May 2016
Proposal to award sole supply of bortezomib in DHB hospitals
As Velcade is currently the only funded brand of bortezomib, there would be no funded brand change resulting from this ...
Posted by Michael Wonder on 16 May 2016
PHARMAC’s new approach for people with rare disorders
16 May 2016 - A new approach PHARMAC has used for funding medicines for rare disorders is gaining real traction, says ...
Posted by Michael Wonder on 12 May 2016
Decision to list bedaquiline (Sirturo) and siltuximab (Sylvant) for rare disorders
12 May 2016 - PHARMAC is pleased to announce the approval of an agreement with Janssen-Cilag for the listing of bedaquiline ...